1
|
Morais SL, Magalhães JMCS, Domingues VF, Delerue-Matos C, Ramos-Jesus J, Ferreira-Fernandes H, Pinto GR, Santos M, Barroso MF. Development of an electrochemical DNA-based biosensor for the detection of the cardiovascular pharmacogenetic-altering SNP CYP2C9*3. Talanta 2023; 264:124692. [PMID: 37276677 DOI: 10.1016/j.talanta.2023.124692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 05/15/2023] [Accepted: 05/18/2023] [Indexed: 06/07/2023]
Abstract
Cardiovascular diseases are among the major causes of mortality and morbidity. Warfarin is often prescribed for these disorders, an anticoagulant with inter and intra-dosage variability dose required to achieve the target international normalized ratio. Warfarin presents a narrow therapeutic index, and due to its variability, it can often be associated with the risk of hemorrhage, or in other patients, thromboembolism. Single-nucleotide polymorphisms are included in the causes that contribute to this variability. The Cytochrome P450 (CYP) 2C9*3 genetic polymorphism modifies its enzymatic activity, and hence warfarin's plasmatic concentration. Thus, the need for a selective, rapid, low-cost, and real-time detection device is crucial before prescribing warfarin. In this work, a disposable electrochemical DNA-based biosensor capable of detecting CYP2C9*3 polymorphism was developed. By analyzing genomic databases, two specific 78 base pairs DNA probes; one with the wild-type adenine (Target-A) and another with the cytosine (Target-C) single-nucleotide genetic variation were designed. The biosensor implied the immobilization on screen-printed gold electrodes of a self-assembled monolayer composed by mercaptohexanol and a linear CYP2C9*3 DNA-capture probe. To improve the selectivity and avoid secondary structures a sandwich format of the CYP2C9*3 allele was designed using complementary fluorescein isothiocyanate-labeled signaling DNA probe and enzymatic amplification of the electrochemical signal. Chronoamperometric measurements were performed at a range of 0.015-1.00 nM for both DNA targets achieving limit of detection of 42 p.m. The developed DNA-based biosensor was able to discriminate between the two synthetic target DNA targets, as well as the targeted denatured genomic DNA, extracted from volunteers genotyped as non-variant homozygous (A/A) and heterozygous (A/C) of the CYP2C9*3 polymorphism.
Collapse
Affiliation(s)
- Stephanie L Morais
- REQUIMTE/LAQV, ISEP, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 4249-015, Porto, Portugal
| | - Júlia M C S Magalhães
- REQUIMTE/LAQV, Departamento de Engenharia Química, Faculdade de Engenharia, Universidade Do Porto, Rua Dr. Roberto Frias, 4200-465, Porto, Portugal
| | - Valentina F Domingues
- REQUIMTE/LAQV, ISEP, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 4249-015, Porto, Portugal.
| | - Cristina Delerue-Matos
- REQUIMTE/LAQV, ISEP, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 4249-015, Porto, Portugal
| | - Joilson Ramos-Jesus
- Faculdade de Ciências Humanas, Exatas e da Saúde Do Piauí (FAHESP)/Instituto de Educação Superior Do Vale Do Parnaíba (IESVAP), R. Evandro Lins e Silva, 4435, 64.212-790, Parnaíba, PI, Brazil
| | - Hygor Ferreira-Fernandes
- Instituto de Educação, Ciência e Técnologia Do Piauí (IFPI), Departamento de Informação, Ambiente, Saúde e Produção Alimentícia, Teresina, PI, Brazil
| | - Giovanny R Pinto
- Grupo de Estudos Em Genética Humana e Médica (GEHMED), Laboratório de Genética e Biologia Molecular, Departamento de Biomedicina, Universidade Do Delta Do Parnaíba (UFDPar), Parnaíba, PI, Brazil
| | - Marlene Santos
- CISA|ESS, Centro de Investigação Em Saúde e Ambiente, Escola Superior de Saúde, Instituto Politécnico Do Porto, Rua Dr. António Bernardino de Almeida, 400, 4200-072, Porto, Portugal; Grupo de Oncologia Molecular e Patologia Viral, Centro de Investigação, Instituto Português de Oncologia Do Porto - Francisco Gentil, R. Dr. António Bernardino de Almeida 865, 4200-072, Porto, Portugal.
| | - M Fátima Barroso
- REQUIMTE/LAQV, ISEP, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 4249-015, Porto, Portugal.
| |
Collapse
|
2
|
Pirolli R, de Alencar VTL, Estati FL, Ribeiro ARG, Honda DYT, de Oliveira M, da Silveira Nogueira Lima JP, Dos Santos ES, Guimarães APG, Baiocchi G, da Costa AABA. Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort. BMC Cancer 2021; 21:525. [PMID: 33964923 PMCID: PMC8106841 DOI: 10.1186/s12885-021-08270-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Accepted: 04/23/2021] [Indexed: 12/09/2022] Open
Abstract
Background Benefit of carboplatin and dose-dense weekly paclitaxel (ddCT) in first line treatment of ovarian cancer patients has been different in Western and Asian studies. In the present study we compare progression-free survival (PFS) of ddCT to three-weekly carboplatin and paclitaxel (CT) in first-line treatment of ovarian carcinoma in a single institution in a Western population. Materials and methods We conducted a retrospective review of medical records from patients with ovarian carcinoma treated in a tertiary cancer center from 2007 to 2018. All patients treated with ddCT or CT in the first-line setting were included. Patients who received first-line bevacizumab were not included. PFS and overall survival (OS) were compared in a propensity score-matched cohort to address selection bias. Patients were matched according to age, ECOG performance status, CA 125, FIGO stage, residual disease, and histological subtype, in a 1:2 ratio. Results Five hundred eighty-eight patients were eligible for propensity score matching, the final cohort consisted of 69 patients treated with ddCT and 138 CT group. Baseline characteristics were well-balanced. After a median follow-up of 65.1 months, median PFS was 29.3 vs 20.0 months, favouring ddCT treatment (p = 0.035). In the multivariate cox regression ddCT showed a 18% lower risk of progression (HR 0.82, 95% CI 0.68–0.99, p = 0.04). Overall survival data is immature, but suggested better outcomes for ddCT (not reached versus 78.8 months; p = 0.07). Conclusion Our retrospective study has shown superior PFS of ddCT over CT regimen in first-line treatment of ovarian carcinoma in a Western population not treated with bevacizumab.
Collapse
Affiliation(s)
- Rafaela Pirolli
- Department of Medical Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | - Viviane Teixeira Loiola de Alencar
- Department of Medical Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | - Felipe Leonardo Estati
- Department of Medical Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | - Adriana Regina Gonçalves Ribeiro
- Department of Medical Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | - Daniella Yumi Tsuji Honda
- Department of Medical Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | - Mariana de Oliveira
- Department of Medical Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | | | - Elizabeth Santana Dos Santos
- Department of Medical Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | - Andrea Paiva Gadelha Guimarães
- Department of Medical Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | - Glauco Baiocchi
- Department of Gynecologic Oncology, A.C. Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, Sao Paulo, SP, 01509-900, Brazil
| | | |
Collapse
|